EUVIMEDOpdag EUVIMED
StudienprotokollOpen access · CC BY-NC 4.0

Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol

Randomisierte kontrollierte multizentrische Studie zur Wirksamkeit einer mobilen KI-Lösung für die diabetesadaptierte Versorgung: MELISSA-Studienprotokoll

Elisabeth J den Brok iD, Cecilie H Svensson, Mikkel T Olsen, Nefeli M Dimitropoulou, Sander M J van Kuijk, Maria Panagiotou, Lubnaa Abdur Rahman, Stephan Proennecke, Peter R Mertens, Stavros Athanasopoulos iD, Cassy F Dingena, Konstantinos Makrilakis and 4 more

Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 6576-6583

DOI: 10.1111/dom.70879 ↗

Auf einen Blick

Die MELISSA-Studie prüft bei Typ-1-Diabetes unter MDI eine KI-gestützte Versorgung mit personalisierten Insulindosen und automatischer Kohlenhydrat-Schätzung. Ein Effekt auf die glykämische Kontrolle wird untersucht.

Fragestellung

Wie wirksam ist das MELISSA-System bei Menschen mit Typ-1-Diabetes unter MDI im Vergleich zur üblichen Versorgung?

Methode

22-wöchige europäische multizentrische, prospektive randomisierte Open-label-Studie mit verblindetem Endpunkt; Typ 1 (n = 278) und explorativ Typ 2 (n = 50). Randomisierung 1:1 nach 6 Wochen Initialisierung.

Ergebnisse

Primärer Endpunkt ist die zwischen den Gruppen unterschiedliche Änderung der Zeit im Zielbereich (3,9–10,0 mmol/L [70–180 mg/dL]) von Baseline bis Studienende. Sekundär: weitere glykämische Parameter, patientenberichtete Outcomes und Sicherheit.

Schlussfolgerung der Autor:innen

Das MELISSA-System könnte die glykämische Kontrolle und die Lebensqualität bei Typ-1-Diabetes unter MDI verbessern. Die Studienergebnisse sollen Daten für die CE-Zertifizierung liefern.

Kernaussagen

  • KI-gestützte Insulinanpassung und Kohlenhydrat-Schätzung werden geprüft
  • Primärer Endpunkt: Zeit im Zielbereich von 3,9–10,0 mmol/L
  • Explorative Kohorte mit Typ-2-Diabetes wird auf Machbarkeit untersucht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Studienprotokoll in Diabetes, Obesity and Metabolism, published online on 2026-05-19. Written by Elisabeth J den Brok and 15 co-authors. Institution: CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands. Major MEDLINE topics: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Insulin, Hypoglycemic Agents. Cited 2 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: European Union, European Commission.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Achieving optimal glycaemic control remains a burden for many people with diabetes on intensive insulin treatment. The MELISSA trial aims to clinically validate the artificial intelligence (AI)‐based MELISSA system to support people with Type 1 diabetes on multiple daily insulin injections (MDI) with personalised insulin dose recommendations and an innovative approach for automatic carbohydrate estimation. In addition, feasibility will be explored in people with Type 2 diabetes. Materials and Methods The MELISSA trial is a 22‐week European multicentre, prospective randomised open‐label blinded endpoint trial including people with Type 1 ( n = 278) and an exploratory cohort of people with Type 2 diabetes ( n = 50) on MDI. The MELISSA system consists of two AI‐driven features: an adaptive basal‐bolus advisor (ABBA), which can be supported by an automated dietary assessment system, goFOOD TM . ABBA provides personalised suggestions for basal insulin and mealtime insulin doses, while goFOOD TM converts food images into carbohydrate content estimations. After the initialisation period (Weeks 0–6), participants will be randomised 1:1 to either the MELISSA system or the continuation of usual care.

Results

The primary endpoint is the between‐group change in percentage of time spent in the target range (3.9–10.0 mmol/L [70–180 mg/dL]) from baseline to study end. Secondary outcomes include additional glycaemic metrics, patient‐reported‐outcomes, and safety information. The trial was approved by the Sponsor's Medical Ethics Research Committee (NL‐009099).

Conclusion

The MELISSA system will potentially improve glycaemic control and quality of life in people with Type 1 diabetes on MDI. The trial outcomes will provide necessary input for obtaining Conformité Européenne certification (class IIb) for the MELISSA system.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2InsulinHypoglycemic AgentsArtificial IntelligenceMobile ApplicationsHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicProspective StudiesFemaleIntelligent SystemsBlood GlucoseGlycemic ControlMaleContinuous Glucose MonitoringGlycated Hemoglobin

Author keywords

artificial intelligenceautomatic carbohydrate countingbasal‐bolus calculatorcontinuous glucose monitoringdiabetes managementdiabetes technologyinsulin therapy

Substances

InsulinHypoglycemic AgentsBlood GlucoseGlycated Hemoglobin

Authors and institutions

  • CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands.
  • Department of Endocrinology and Nephrology, Copenhagen University Hospital-North Zealand, Hillerod, Denmark.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.

ORCID profiles: Elisabeth J den Brok, Stavros Athanasopoulos, Ulrik Pedersen-Bjergaard

Funding

  • European Union
  • European Commission

Cite

APA

den Brok, E. J., Svensson, C. H., Olsen, M. T., Dimitropoulou, N. M., van Kuijk, S. M. J., Panagiotou, M., Abdur Rahman, L., Proennecke, S., Mertens, P. R., Athanasopoulos, S., Dingena, C. F., Makrilakis, K., Mougiakakou, S., Pedersen-Bjergaard, U., de Galan, B. E., & MELISSA consortium (2026). Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol. Diabetes, Obesity and Metabolism, 28(8), 6576-6583. https://doi.org/10.1111/dom.70879

Vancouver

den Brok EJ, Svensson CH, Olsen MT, Dimitropoulou NM, van Kuijk SMJ, Panagiotou M, et al. Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol. Diabetes, Obesity and Metabolism. 2026;28(8):6576-6583. doi:10.1111/dom.70879

BibTeX
@article{denBrok2026,
  author = {den Brok, Elisabeth J and Svensson, Cecilie H and Olsen, Mikkel T and Dimitropoulou, Nefeli M and van Kuijk, Sander M J and Panagiotou, Maria and Abdur Rahman, Lubnaa and Proennecke, Stephan and Mertens, Peter R and Athanasopoulos, Stavros and Dingena, Cassy F and Makrilakis, Konstantinos and Mougiakakou, Stavroula and Pedersen-Bjergaard, Ulrik and de Galan, Bastiaan E and MELISSA consortium, MELISSA consortium},
  title = {Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {6576--6583},
  doi = {10.1111/dom.70879}
}
Start for free →